Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2003 · 2.9K citations

Medicine, Oncology, Pharmacology +13

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA · 2003 · 2.5K citations

Medicine, Oncology, Pharmacology +17

Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

Julian Downward, Yosef Yarden, E. L. V. Mayes et al. · Nature · 1984 · 2.5K citations · Full text

Medicine, Genetics, Molecular Biology +10